Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioNexus Gene Lab (BGLC) Capital Expenditures (2018 - 2025)

Historic Capital Expenditures for BioNexus Gene Lab (BGLC) over the last 8 years, with Q3 2025 value amounting to $5483.0.

  • BioNexus Gene Lab's Capital Expenditures fell 9724.73% to $5483.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $40016.0, marking a year-over-year decrease of 8212.81%. This contributed to the annual value of $226989.0 for FY2024, which is 5193.58% up from last year.
  • Per BioNexus Gene Lab's latest filing, its Capital Expenditures stood at $5483.0 for Q3 2025, which was down 9724.73% from $21459.0 recorded in Q2 2025.
  • In the past 5 years, BioNexus Gene Lab's Capital Expenditures registered a high of $199189.0 during Q3 2024, and its lowest value of $102.0 during Q1 2023.
  • Over the past 5 years, BioNexus Gene Lab's median Capital Expenditures value was $4022.0 (recorded in 2024), while the average stood at $24721.8.
  • Examining YoY changes over the last 5 years, BioNexus Gene Lab's Capital Expenditures showed a top increase of 3340000.0% in 2021 and a maximum decrease of 9969.64% in 2021.
  • Quarter analysis of 5 years shows BioNexus Gene Lab's Capital Expenditures stood at $1279.0 in 2021, then skyrocketed by 1231.27% to $17027.0 in 2022, then crashed by 94.5% to $937.0 in 2023, then skyrocketed by 329.24% to $4022.0 in 2024, then surged by 36.33% to $5483.0 in 2025.
  • Its last three reported values are $5483.0 in Q3 2025, $21459.0 for Q2 2025, and $9052.0 during Q1 2025.